FASEB SRC on Hematopoietic Malignancies

FASEB SRC 造血系统恶性肿瘤

• 批准号: 8199824
• 负责人: John D Crispino
• 金额: $ 0.5万
• 依托单位: FEDERATION OF AMER SOC FOR EXPER BIOLOGY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-07-01 至 2012-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8199824
• 关键词: Academy; Acute Lymphocytic Leukemia; Acute Myelocytic Leukemia; Acute Promyelocytic Leukemia; Adult; American Society of Hematology; Animal Model; Area; Arsenic Trioxide; Basic Science; Biological Markers; Biology; Cells; Childhood; Chromatin Structure; Chromosomal translocation; Chronic Myeloid Leukemia; Clinical; Clinical Trials; Collaborations; Commit; DNA Methylation; Development; Disease; Environment; Fostering; Genomics; Gleevec; Goals; Hematologic Neoplasms; Hematological Disease; Hematopoiesis; Hematopoietic; Hematopoietic Neoplasms; Histone Acetylation; Human Genome Project; Investigation; JAK2 gene; Journals; Learning; Malignant Neoplasms; Metabolic; Methylation; MicroRNAs; Molecular; Morbidity - disease rate; Multiple Myeloma; Mutation; Myeloproliferative disease; Participant; Pathogenesis; Pathologic; Patients; Pharmaceutical Preparations; Physicians; Postdoctoral Fellow; Publications; Research; Research Personnel; Resistance; Role; Rural; Schools; Scientist; Signal Transduction; Site; Staging; Stem cells; Students; Syndrome; Systems Biology; Therapeutic; Training; Transcriptional Regulation; Travel; Tretinoin; United States National Institutes of Health; Vermont; Yang; base; cancer cell; cancer diagnosis; cancer therapy; distraction; functional genomics; graduate student; improved; inhibitor/antagonist; interest; leukemia; leukemia/lymphoma; meetings; mortality; notch protein; novel; novel therapeutics; oncology; physical science; protein protein interaction; stem; stem cell biology; stem cell therapy; success; symposium

DESCRIPTION (provided by applicant): The FASEB Summer Research Conference on Hematopoietic Malignancies is a highly focused and interactive meeting of physicians and scientists who are dedicated to the study of blood diseases and are committed to developing improved therapies for patients. Unlike the annual American Society of Hematology Meeting, which draws well over 15,000 participants, the FASEB meeting, is restricted to 175 attendees and thus provides a collaborative and supportive environment for trainees to meet with leaders in the field. The 2011 meeting will highlight recent advances in biology and treatment of a wide spectrum of blood cancers, including acute myeloid leukemia, acute lymphoid leukemia, myeloma, myeloproliferative neoplasms and myeloproliferative diseases. In addition, this year's meeting will include sessions on systems biology of hematopoiesis, stem cell biology, and the role of metabolic mutations in hematologic malignancies. We will hold special "Meet the Expert" and "Meet the Editor" sessions, where trainees can interact one on one with leaders in the field and with Dr. Helena Yang, editor of the journal Cancer Cell. The site of the 2011 meeting will once again be the Vermont Academy, a small boarding school in rural Vermont. This site is an ideal setting, because the participants have few distractions and are available to interact with students and post-docs throughout the day. The meeting will emphasize the following key areas: 1) The identification of oncometabolites and their implications for blood cancer treatment and diagnosis; 2) Normal hematopoietic stem and progenitor cell development for understanding leukemia stem cell (LSC) biology; 3) Mechanisms of altered transcriptional regulation in hematopoietic neoplasms, with a particular focus on changes in DNA methylation as well as histone acetylation, methylation and chromatin structure; 4) Role of microRNAs in CLL pathogenesis and as cancer biomarkers; 5) Lessons learned from the use of animal models; identification of LSCs and anti- LSC therapies; 6) The impact of the human genome project in investigations of hematological malignancies, with an emphasis on functional genomics; 7) Application of systems biology approaches to hematopoietic malignancies and LSC biology; and 8) Recent therapeutic advances based on a molecular understanding of the diseases; e.g. Notch inhibitors in T-ALL; mechanisms of Gleevec resistance and sensitivity in chronic myeloid leukemia, use of arsenic trioxide in APL and CLL, and efforts to utilize JAK inhibitors in myeloproliferative neoplasms. Support from the NIH will be used to provide registration and lodging for trainees and early stage investigators and a small subset of invited speakers. PUBLIC HEALTH RELEVANCE: Although there have been major breakthroughs in treating a few subtypes of hematologic malignancies, such as the use of Gleevec in chronic myeloid leukemia, the majority of blood cancers remain major causes of morbidity and mortality of both adult and pediatric patients. The FASEB Summer Research Conference on Hematopoietic Malignancies serves to bring together basic, translational, and clinical researchers for an insightful and productive exchange of latest discoveries. The meeting also fosters new collaborations and the training of graduate students, post---doctoral fellows and early stage investigators in this important research field.

描述（由申请人提供）：FASEB 造血系统恶性肿瘤夏季研究会议是一次高度集中且互动的会议，由致力于血液疾病研究并致力于为患者开发改进疗法的医生和科学家组成。与每年吸引超过 15,000 名与会者的美国血液学会会议不同，FASEB 会议仅限 175 名与会者，因此为学员提供了一个与该领域领导者会面的协作和支持环境。 2011 年会议将重点介绍多种血癌的生物学和治疗方面的最新进展，包括急性髓性白血病、急性淋巴性白血病、骨髓瘤、骨髓增殖性肿瘤和骨髓增殖性疾病。此外，今年的会议还将包括造血系统生物学、干细胞生物学以及代谢突变在血液恶性肿瘤中的作用等会议。我们将举办专门的“会见专家”和“会见编辑”课程，学员可以与该领域的领导者以及《Cancer Cell》杂志的编辑Helena Yang博士进行一对一的互动。 2011 年会议的举办地点将再次是佛蒙特州学院，这是佛蒙特州乡村地区的一所小型寄宿学校。该网站是一个理想的环境，因为参与者几乎没有干扰，并且可以全天与学生和博士后互动。会议将强调以下关键领域：1）致癌代谢物的鉴定及其对血癌治疗和诊断的影响； 2）正常造血干细胞和祖细胞发育，以了解白血病干细胞（LSC）生物学； 3）造血系统肿瘤转录调控改变的机制，特别关注DNA甲基化以及组蛋白乙酰化、甲基化和染色质结构的变化； 4) microRNA在CLL发病机制中的作用以及作为癌症生物标志物的作用； 5）从使用动物模型中吸取的教训； LSC 的鉴定和抗 LSC 疗法； 6）人类基因组计划对血液恶性肿瘤研究的影响，重点是功能基因组学； 7) 系统生物学方法在造血系统恶性肿瘤和LSC生物学中的应用； 8) 基于对疾病的分子理解的最新治疗进展；例如T-ALL 中的 Notch 抑制剂；慢性粒细胞白血病的格列卫耐药性和敏感性机制、三氧化二砷在 APL 和 CLL 中的应用，以及在骨髓增殖性肿瘤中利用 JAK 抑制剂的努力。美国国立卫生研究院的支持将用于为学员、早期研究人员以及一小部分受邀演讲者提供注册和住宿。 公共健康相关性：尽管在治疗几种血液恶性肿瘤亚型方面取得了重大突破，例如格列卫用于治疗慢性粒细胞白血病，但大多数血癌仍然是成人和儿童患者发病和死亡的主要原因。 FASEB 造血系统恶性肿瘤夏季研究会议旨在将基础、转化和临床研究人员聚集在一起，就最新发现进行富有洞察力和富有成效的交流。会议还促进了这一重要研究领域的新合作以及对研究生、博士后研究员和早期研究人员的培训。